Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
No previous study has assessed whether the addition of metformin potentiates fibrate action on hemostasis in prediabetic subjects. Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo. Twelve-week treatment with fenofibrate and metformin reduced plasma levels of fibrinogen and PAI-1 and tended to change the other hemostatic markers measured, as well as improved insulin sensitivity. Our results show that high-dose metformin exhibits beneficial effects on coagulation and fibrinolysis in isolated IGT patients treated with a fibrate.